123i-bmipp
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00514501)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fatty acid-binding protein 9BINDING AGENT
FABP9 binding agent
Chemistry & pharmacology
- Imaging
- 123-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111094 ↗
- ChEMBLCHEMBL2107345 ↗
Also known as
- 15-(4-iodophenyl)-3-methylpentadecanoic acid
- 15-(4-iodophenyl)-3-methylpentadecanoic acid, (+-)-isomer, 123i-labeled
- 15-p-iodophenyl-beta-methylpentadecanoic acid
- 3-methyl-4-iodophenylpentadecanoic acid
- (3rs)-15-(4-((sup 123)i)iodophenyl)-3-methylpentadecanoic acid
- beta-methyl-15-(4-iodophenyl)pentadecanoic acid
- bmipp
- bmipp
- bmipp
- bmpda
- iodofiltic acid
- iodofiltic acid
- iodofiltic acid
- iodofiltic acid
- iodofiltic acid (123i)
- iodofiltic acid (123i)
- iodofiltic acid (123i)
- iodofiltic acid i 123
- iodofiltic acid i 123
- iodofiltic acid i 123
- zemiva
- zemiva
- zemiva
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02975986 | N/A | Jan 31, 2017 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The University of Texas, Dallas |
| NCT00514501 | Phase 2 | May 1, 2007 | Molecular Insight Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Molecular Insight Pharmaceuticals | For profit | 1 | 1 | 1 | 2007 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2017 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1